Serum level of proteins involved in apoptosis and autophagy in patients with type 2 diabetes and non-alcoholic fatty liver disease

QR Code

Serum level of proteins involved in apoptosis and autophagy in patients with type 2 diabetes and non-alcoholic fatty liver disease

Aim of the study was to estimate the blood serum level of microtubule-associated protein 1 light chain 3 alpha (MAP1LC3alpha), beclin-1 (BECN-1), Bcl-2 (BCL-2), caspase-3 (CASP3) and autophagy related 5 (ATG-5) protein as potential markers of liver fibrosis in type 2 diabetes (T2D) patients with non...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ya. A. Krasner, V. V. Romanov, O. N. Fazullina, M. F. Osipenko, V. V. Klimontov
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Siberian Branch Publishing House 2024-01-01
Series:	Сибирский научный медицинский журнал
Subjects:	diabetes mellitus type 2 non-alcoholic fatty liver disease liver fibrosis biomarker apoptosis autophagy transient liver elastograрhy
Online Access:	https://sibmed.elpub.ru/jour/article/view/1320
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hepatogenic weakness as a clinical marker of hyperammonemia and of the effectiveness of its correction in patients with pre-cirrhotic stages of non-alcoholic fatty liver disease
by: E. M. Petrova, et al.
Published: (2021-06-01)

Features of cellular immunity and regeneration for alcoholic fibrosis of the liver
by: N. D. Gazatova, et al.
Published: (2019-05-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

CORRECTION OF MICROCIRCULATORY DISORDERS IN NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHRONIC HEART FAILURE PATIENTS
by: M. E. Statsenko, et al.
Published: (2016-12-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors
by: Ignatius Bima Prasetya, et al.
Published: (2017-08-01)

Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors
by: Ignatius Bima Prasetya, et al.
Published: (2017-08-01)

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease
by: T. S. Krolevets, et al.
Published: (2020-12-01)

Comparison of Transient Elastography and Liver Biopsy in Assessing Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Gaurav Bachhav, et al.
Published: (2021-05-01)

Non-alcoholic fatty liver disease and metabolic liver dysfunction in the new coronavirus infection COVID-19
by: A. A. Karaseva, et al.
Published: (2021-12-01)

Liver Cirrhosis as the Outcome of Non-Alcoholic Fatty Liver Disease Associated with PNPLA3 Gene RS738409 Polymorphism
by: I. G. Nikitin, et al.
Published: (2020-03-01)

Tuning Autophagy for Improved Liver Transplant Outcomes: Insights from Experimental Models
by: Mina Kolahdouzmohammadi, et al.
Published: (2025-05-01)

Assessment of the dynamics of autophagy and apoptosis biomarkers in the acute period of ischemic stroke using flow cytometry
by: A. V. Lugovaya, et al.
Published: (2022-07-01)

PATOMORFOLOGICHESKY ASSESSMENT ETHANOL POISONING AMID ALCOHOLIC LIVER DISEASE
by: E. N. Travenko, et al.
Published: (2017-07-01)

Programmed cell death and liver diseases
by: N. A. Onishchenko, et al.
Published: (2022-04-01)

The role of apoptotic bone marrow cells in activation of liver regeneration
by: N. A. Onishchenko, et al.
Published: (2022-01-01)

Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
by: Zhiqing Zhang, et al.
Published: (2025-06-01)

Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data)
by: S. E. Evstifeeva, et al.
Published: (2022-10-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease)
by: Alexander A. Baranov, et al.
Published: (2025-05-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Association of the p.I148m polymorphism in the <i>PNPLA3</i> gene with the severity of nonalcoholic fatty liver disease in various clinical groups
by: D. V. Sidorenko, et al.
Published: (2024-04-01)

Modern concepts on pathogenetic mechanisms of liver fibrosis
by: N. A. Efremova, et al.
Published: (2023-04-01)

Diagnostics of Fibrosis in Alcoholic Liver Damage
by: E. N. Travenko, et al.
Published: (2019-09-01)

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
by: Pojsakorn Danpanichkul, et al.
Published: (2025-07-01)

Non-alcoholic fatty liver disease and cardiovascular pathology: pathogenetic parallels
by: G. Yu. Knorring, et al.
Published: (2024-08-01)

Alcohol-induced liver disease: primary and secondary prevention
by: S. V. Plyusnin, et al.
Published: (2015-07-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

Impact of the growth hormone and IGF-1 on graft function and immune response in pediatric liver recipients
by: R. M. Kurabekova, et al.
Published: (2022-07-01)

Hepato-Renal Crosstalk in Acute and Chronic Disease: From Shared Pathways to Therapeutic Targets
by: Anna Clementi, et al.
Published: (2025-07-01)

The diagnostic value of indirect markers of liver fibrosis in patients with chronic hepatitis B
by: D. V. Tereshkov, et al.
Published: (2020-03-01)

PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 MEASUREMENT IN PATIENTS WITH METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE
by: O. M. Drapkina, et al.
Published: (2015-10-01)

Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosis
by: Benedict T.K. Vanlerberghe, et al.
Published: (2025-08-01)

Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies)
by: O. M. Drapkina, et al.
Published: (2025-03-01)

Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility
by: Dongyao Wang, et al.
Published: (2025-07-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Body Mass Index and Indicators of Lipid Exchange in Liver Steatosis of Alcoholic and Nonalcoholic Genesis in Residents of Rural Area: Similarities and Differences
by: N. V. Mikhaylova, et al.
Published: (2019-07-01)

Real-World Clinical and Economic Efficacy of Succinate-Based Therapy with Remaxol of Alcohol Hepatitis
by: L. Yu. Il’chenko, et al.
Published: (2024-02-01)

First living donor liver transplantation for congenital hepatic fi brosis in Azerbaijan
by: R. A. Mamedov, et al.
Published: (2017-06-01)